UK Pharma's 'Brexit Playbook' Might Envision New Regulator Roles
Britain's life sciences sector is compiling detailed game plan for September talks with the new Conservative government to promote its interests once the UK leaves the EU. All options are being considered – including possible establishment of a best-in-class regulatory agency in Britain.
You may also be interested in...
AstraZeneca’s total focus on its core therapy areas will ensure it keeps building external collaborations and doing deals to generate new therapies while maximizing revenues, but outright sales of non-core mature medicines are likely to be fewer going forward, according to the company’s head of business development.
GlaxoSmithKline reported a strong second quarter and along with its core EPS guidance upgrade, this adds momentum to its post-Brexit vote boost.
Theresa May has re-structured the Department of Health ministerial team as part of her wide-ranging reshuffle and in so doing moved life sciences minister George Freeman over to chair the prime minister’s policy board. The British biopharma community says it hopes he will be replaced – and soon.